Your browser is no longer supported. Please, upgrade your browser.
Settings
VRPX [NASD]
Virpax Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.56 Insider Own0.10% Shs Outstand4.96M Perf Week-50.52%
Market Cap67.39M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.06M Perf Month-74.93%
Income-7.10M PEG- EPS next Q- Inst Own4.60% Short Float11.91% Perf Quarter48.32%
Sales- P/S- EPS this Y-31.20% Inst Trans-7.85% Short Ratio0.04 Perf Half Y8.30%
Book/sh1.52 P/B3.78 EPS next Y- ROA- Target Price- Perf Year-
Cash/sh0.89 P/C6.42 EPS next 5Y- ROE- 52W Range3.70 - 36.00 Perf YTD-12.10%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-84.06% Beta-
Dividend %- Quick Ratio4.00 Sales past 5Y- Gross Margin- 52W Low55.14% ATR2.86
Employees2 Current Ratio4.00 Sales Q/Q- Oper. Margin- RSI (14)34.51 Volatility13.54% 17.42%
OptionableNo Debt/Eq0.15 EPS Q/Q29.30% Profit Margin- Rel Volume0.12 Prev Close5.75
ShortableYes LT Debt/Eq0.13 Earnings- Payout- Avg Volume6.21M Price5.74
Recom- SMA20-61.04% SMA50-38.44% SMA200-7.93% Volume741,447 Change-0.17%
Sep-16-21 01:00PM  
Sep-14-21 02:49PM  
12:27PM  
10:11AM  
09:05AM  
Sep-13-21 07:07AM  
Sep-02-21 09:00AM  
Aug-26-21 02:51PM  
09:00AM  
Aug-19-21 07:07AM  
05:11AM  
Aug-18-21 02:30PM  
12:09PM  
12:00PM  
10:45AM  
10:33AM  
08:50AM  
07:07AM  
Aug-17-21 02:47PM  
02:31PM  
09:00AM  
Aug-10-21 09:00AM  
Jul-30-21 09:00AM  
Jul-07-21 09:00AM  
Jun-21-21 08:00AM  
Jun-02-21 08:00AM  
May-18-21 08:00AM  
Apr-22-21 08:00AM  
Apr-19-21 12:14PM  
09:00AM  
Apr-05-21 12:54PM  
09:00AM  
Mar-22-21 09:00AM  
Mar-10-21 09:00AM  
Mar-02-21 08:00AM  
Mar-01-21 11:15AM  
Feb-23-21 08:00AM  
Feb-22-21 01:52PM  
Feb-19-21 04:07PM  
Virpax Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company, develops and manufactures non-opioid and non-addictive pharmaceutical products using drug delivery systems for pain management. The company offers products, such as Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; Probudur (LBL100), long-acting bupivacaine liposomal gel for postoperative pain management; OSF200 for chronic osteoarthritis of the knee; and NES100 (Envelta), an exogenous enkephalin intranasal spray for acute and chronic pain. It also develops PES200 for the management of post-traumatic stress disorder; and MMS019 high-density molecular masking spray to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jambulingam ThaniDirectorFeb 17Buy7.16100716100Mar 01 06:00 PM